Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 266

1.

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC.

Blood Cancer J. 2020 Feb 13;10(2):17. doi: 10.1038/s41408-020-0273-x. Review.

PMID:
32054831
2.

Bacterial Infection Among Patients With Multiple Myeloma Treated With Bortezomib-based Induction Therapy: Real-World Experience in an Asian Cancer Center.

Soekojo CY, Low JZ, Oh J, Ooi M, De Mel S, Chng WJ.

Clin Lymphoma Myeloma Leuk. 2020 Jan 9. pii: S2152-2650(20)30009-4. doi: 10.1016/j.clml.2019.12.024. [Epub ahead of print]

PMID:
32019731
3.

Application of an ex-vivo drug sensitivity platform towards achieving complete remission in a refractory T-cell lymphoma.

de Mel S, Rashid MBM, Zhang XY, Goh J, Lee CT, Poon LM, Chan EHL, Liu X, Chng WJ, Chee YL, Lee J, Yuen YC, Lim JQ, Chia BKH, Laurensia Y, Huang D, Pang WL, Cheah DMZ, Wong EKY, Ong CK, Tang T, Lim ST, Ng SB, Tan SY, Loi HY, Tan LK, Chow EK, Jeyasekharan AD.

Blood Cancer J. 2020 Jan 27;10(1):9. doi: 10.1038/s41408-020-0276-7. No abstract available.

4.

Enabling Technologies for Personalized and Precision Medicine.

Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A.

Trends Biotechnol. 2020 Jan 21. pii: S0167-7799(19)30316-6. doi: 10.1016/j.tibtech.2019.12.021. [Epub ahead of print] Review.

PMID:
31980301
5.

Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing.

Choo QWW, Koean RAG, Chang SC, Chng WJ, Chan MC, Wang W, Er JZ, Ding JL.

Immunol Cell Biol. 2020 Feb;98(2):138-151. doi: 10.1111/imcb.12309. Epub 2020 Jan 13.

6.

Liquid biopsy for minimal residual disease detection in leukemia using a portable blast cell biochip.

Khoo BL, Shang M, Ng CH, Lim CT, Chng WJ, Han J.

NPJ Precis Oncol. 2019 Dec 2;3:30. doi: 10.1038/s41698-019-0102-5. eCollection 2019.

7.

circASXL1-1 regulates BAP1 deubiquitinase activity in leukemia.

Jadhav S, Kumari N, Ng L, Tan PF, Yeo-Teh NSL, Goh Y, Fam WN, Tng JQ, Tian JS, Koh BTH, Chun CM, Wang W, Chng WJ, Fullwood MJ, Guccione E, Karnani N, Tenen DG, Jha S.

Haematologica. 2019 Nov 28. pii: haematol.2019.225961. doi: 10.3324/haematol.2019.225961. [Epub ahead of print] No abstract available.

8.

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.

Li B, Chng WJ.

J Hematol Oncol. 2019 Nov 21;12(1):118. doi: 10.1186/s13045-019-0814-6. Review.

9.

ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia.

Zhou J, Quah JY, Ng Y, Chooi JY, Toh SH, Lin B, Tan TZ, Hosoi H, Osato M, Seet Q, Ooi AGL, Lindmark B, McHale M, Chng WJ.

Haematologica. 2019 Nov 7. pii: haematol.2019.230482. doi: 10.3324/haematol.2019.230482. [Epub ahead of print]

10.

Comprehensive Analysis of ERK1/2 Substrates for Potential Combination Immunotherapies.

Yang L, Zheng L, Chng WJ, Ding JL.

Trends Pharmacol Sci. 2019 Nov;40(11):897-910. doi: 10.1016/j.tips.2019.09.005. Epub 2019 Oct 29. Review.

11.

Discovery of a potent histone deacetylase (HDAC) 3/6 selective dual inhibitor.

Soumyanarayanan U, Ramanujulu PM, Mustafa N, Haider S, Fang Nee AH, Tong JX, Tan KSW, Chng WJ, Dymock BW.

Eur J Med Chem. 2019 Dec 15;184:111755. doi: 10.1016/j.ejmech.2019.111755. Epub 2019 Oct 7.

PMID:
31627059
12.

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.

Soekojo CY, Kim K, Huang SY, Chim CS, Takezako N, Asaoku H, Kimura H, Kosugi H, Sakamoto J, Gopalakrishnan SK, Nagarajan C, Wei Y, Moorakonda R, Lee SL, Lee JJ, Yoon SS, Kim JS, Min CK, Lee JH, Durie B, Chng WJ.

Blood Cancer J. 2019 Oct 8;9(10):83. doi: 10.1038/s41408-019-0245-1.

13.

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.

Zhou J, Chng WJ.

World J Clin Oncol. 2019 Sep 24;10(9):303-306. doi: 10.5306/wjco.v10.i9.303.

14.

MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.

Li B, Yan J, Phyu T, Fan S, Chung TH, Mustafa N, Lin B, Wang L, Eichhorn PJA, Goh BC, Ng SB, Kappei D, Chng WJ.

Blood. 2019 Dec 5;134(23):2046-2058. doi: 10.1182/blood.2019000381.

PMID:
31434700
15.

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in 1q21(amp) multiple myeloma.

Teoh PJ, Chung TH, Chng PYZ, Toh SHM, Chng WJ.

Haematologica. 2019 Aug 14. pii: haematol.2019.221176. doi: 10.3324/haematol.2019.221176. [Epub ahead of print]

16.

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Dimopoulos MA, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH.

Int J Hematol. 2019 Oct;110(4):466-473. doi: 10.1007/s12185-019-02704-z. Epub 2019 Aug 6.

PMID:
31388932
17.

IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.

Chong PSY, Zhou J, Lim JSL, Hee YT, Chooi JY, Chung TH, Tan ZT, Zeng Q, Waller DD, Sebag M, Chng WJ.

Cancer Res. 2019 Sep 15;79(18):4679-4688. doi: 10.1158/0008-5472.CAN-19-0343. Epub 2019 Jul 23.

PMID:
31337650
18.

Super-enhancers: critical roles and therapeutic targets in hematologic malignancies.

Jia Y, Chng WJ, Zhou J.

J Hematol Oncol. 2019 Jul 16;12(1):77. doi: 10.1186/s13045-019-0757-y. Review.

19.

The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma.

Oon ML, Hoppe MM, Fan S, Phyu T, Phuong HM, Tan SY, Hue SS, Wang S, Poon LM, Chan HLE, Lee J, Chee YL, Chng WJ, de Mel S, Liu X, Jeyasekharan AD, Ng SB.

Leuk Lymphoma. 2019 Dec;60(13):3214-3224. doi: 10.1080/10428194.2019.1633629. Epub 2019 Jul 1.

PMID:
31259656
20.

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.

Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q.

Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x.

21.

Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis.

Soekojo CY, Wang GM, Chen Y, Casan J, Wolyncewicz G, Lin A, Poon LM, de Mel S, Koh LP, Tan LK, Ooi MG, Nagarajan C, Liu Y, Lai YY, Huang XJ, Spencer A, Gopalakrishnan SK, Lu J, Chng WJ.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470-e477. doi: 10.1016/j.clml.2019.04.011. Epub 2019 Apr 28.

PMID:
31171473
22.

Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups.

Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, Dimopoulos M.

Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):522-530.e1. doi: 10.1016/j.clml.2019.04.018. Epub 2019 May 2.

23.

STAT3: A Promising Therapeutic Target in Multiple Myeloma.

Chong PSY, Chng WJ, de Mel S.

Cancers (Basel). 2019 May 26;11(5). pii: E731. doi: 10.3390/cancers11050731. Review.

24.

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact.

Li Z, Wong KY, Calin GA, Chng WJ, Chan GC, Chim CS.

Clin Epigenetics. 2019 May 7;11(1):71. doi: 10.1186/s13148-019-0669-2.

25.

Molecular pathogenic pathways in extranodal NK/T cell lymphoma.

de Mel S, Hue SS, Jeyasekharan AD, Chng WJ, Ng SB.

J Hematol Oncol. 2019 Apr 2;12(1):33. doi: 10.1186/s13045-019-0716-7. Review.

26.

Cancer in 2019 - Progress and Challenges - A Perspective.

Chng WJ.

Ann Acad Med Singapore. 2019 Feb;48(2):45-47. No abstract available.

27.

Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.

Hungria VTM, Lee JH, Maiolino A, de Queiroz Crusoe E, Martinez G, Bittencourt R, Duarte GO, Fantl DB, Navarro JR, Conte G, Gomez-Almaguer D, Ruiz-Argüelles GJ, Kim K, Shimizu K, Chen W, Huang SY, Chng WJ, Chim CS, Nawarawong W, Durie B.

Ann Hematol. 2019 Apr;98(4):941-949. doi: 10.1007/s00277-019-03602-4. Epub 2019 Feb 6.

PMID:
30729281
28.

Transcriptomic Abnormalities in Epstein Barr Virus Associated T/NK Lymphoproliferative Disorders.

de Mel S, Tan JZ, Jeyasekharan AD, Chng WJ, Ng SB.

Front Pediatr. 2019 Jan 17;6:405. doi: 10.3389/fped.2018.00405. eCollection 2018. Review.

29.

Towards understanding of PRC2 binding to RNA.

Yan J, Dutta B, Hee YT, Chng WJ.

RNA Biol. 2019 Feb;16(2):176-184. doi: 10.1080/15476286.2019.1565283. Epub 2019 Jan 8. Review.

30.

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.

Lim SL, Damnernsawad A, Shyamsunder P, Chng WJ, Han BC, Xu L, Pan J, Pravin DP, Alkan S, Tyner JW, Koeffler HP.

Haematologica. 2019 Jun;104(6):1209-1220. doi: 10.3324/haematol.2018.201483. Epub 2019 Jan 3.

31.

Clinical benefit of depth of response for relapsed/refractory multiple myeloma patients treated on clinical trials: retrospective analysis from two tertiary centres.

Chan EHL, De-Silva D, Lin AHF, Rabin N, Wechalekar A, Popat R, Chng WJ, Yong KL.

Br J Haematol. 2019 Jul;186(1):162-165. doi: 10.1111/bjh.15743. Epub 2018 Dec 28. No abstract available.

PMID:
30592025
32.

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group.

Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10.

PMID:
30545780
33.

MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.

Xie Z, Chooi JY, Toh SHM, Yang D, Basri NB, Ho YS, Chng WJ.

Leukemia. 2019 Mar;33(3):739-748. doi: 10.1038/s41375-018-0300-0. Epub 2018 Nov 23.

PMID:
30470837
34.

Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.

Rassidakis GZ, Herold N, Myrberg IH, Tsesmetzis N, Rudd SG, Henter JI, Schaller T, Ng SB, Chng WJ, Yan B, Ng CH, Ravandi F, Andreeff M, Kantarjian HM, Medeiros LJ, Xagoraris I, Khoury JD.

Blood Cancer J. 2018 Oct 19;8(11):98. doi: 10.1038/s41408-018-0134-z.

35.

Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia.

Chong PSY, Zhou J, Chooi JY, Chan ZL, Toh SHM, Tan TZ, Wee S, Gunaratne J, Zeng Q, Chng WJ.

Oncogene. 2019 Feb;38(9):1508-1519. doi: 10.1038/s41388-018-0526-3. Epub 2018 Oct 10.

PMID:
30305722
36.

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.

Zhou J, Chng WJ.

World J Clin Oncol. 2018 Sep 14;9(5):90-97. doi: 10.5306/wjco.v9.i5.90. Review.

37.

Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat.

Chu-Farseeva YY, Mustafa N, Poulsen A, Tan EC, Yen JJY, Chng WJ, Dymock BW.

Eur J Med Chem. 2018 Oct 5;158:593-619. doi: 10.1016/j.ejmech.2018.09.024. Epub 2018 Sep 11.

PMID:
30243158
38.

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies.

Arora L, Kumar AP, Arfuso F, Chng WJ, Sethi G.

Cancers (Basel). 2018 Sep 13;10(9). pii: E327. doi: 10.3390/cancers10090327. Review.

39.

LEE011 and ruxolitinib: a synergistic drug combination for natural killer/T-cell lymphoma (NKTCL).

Hee YT, Yan J, Nizetic D, Chng WJ.

Oncotarget. 2018 Aug 7;9(61):31832-31841. doi: 10.18632/oncotarget.25835. eCollection 2018 Aug 7.

40.

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Luchtel RA, Dasari S, Oishi N, Pedersen MB, Hu G, Rech KL, Ketterling RP, Sidhu J, Wang X, Katoh R, Dogan A, Kip NS, Cunningham JM, Sun Z, Baheti S, Porcher JC, Said JW, Jiang L, Hamilton-Dutoit SJ, Møller MB, Nørgaard P, Bennani NN, Chng WJ, Huang G, Link BK, Facchetti F, Cerhan JR, d'Amore F, Ansell SM, Feldman AL.

Blood. 2018 Sep 27;132(13):1386-1398. doi: 10.1182/blood-2018-03-838524. Epub 2018 Aug 9.

41.

Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP).

Rashid MBMA, Toh TB, Hooi L, Silva A, Zhang Y, Tan PF, Teh AL, Karnani N, Jha S, Ho CM, Chng WJ, Ho D, Chow EK.

Sci Transl Med. 2018 Aug 8;10(453). pii: eaan0941. doi: 10.1126/scitranslmed.aan0941.

PMID:
30089632
42.

ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia.

Zhou J, Ng Y, Chng WJ.

Cell Mol Life Sci. 2018 Nov;75(21):3931-3941. doi: 10.1007/s00018-018-2895-8. Epub 2018 Jul 31. Review.

PMID:
30066088
43.

Aberrant hyperediting of the myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis.

Teoh PJ, An O, Chung TH, Chooi JY, Toh SHM, Fan S, Wang W, Koh BTH, Fullwood MJ, Ooi MG, de Mel S, Soekojo CY, Chen L, Ng SB, Yang H, Chng WJ.

Blood. 2018 Sep 20;132(12):1304-1317. doi: 10.1182/blood-2018-02-832576. Epub 2018 Jul 30.

PMID:
30061158
44.

Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma.

Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, Pang WL, Kizhakeyil A, Wijaya GC, Huang DC, Nagarajan S, Chia BK, Cheah D, Liu YH, Zhang F, Rao HL, Tang T, Wong EK, Bei JX, Iqbal J, Grigoropoulos NF, Ng SB, Chng WJ, Teh BT, Tan SY, Verma NK, Fan H, Lim ST, Ong CK.

Blood. 2018 Sep 13;132(11):1146-1158. doi: 10.1182/blood-2018-01-829424. Epub 2018 Jul 27.

45.

BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.

Zhou Y, Zhou J, Lu X, Tan TZ, Chng WJ.

BMC Cancer. 2018 Jul 11;18(1):731. doi: 10.1186/s12885-018-4661-6.

46.

The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.

de Mel S, Soon GS, Mok Y, Chung TH, Jeyasekharan AD, Chng WJ, Ng SB.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1931. doi: 10.3390/ijms19071931. Review.

47.

Potential Clinical Application of Genomics in Multiple Myeloma.

Soekojo CY, de Mel S, Ooi M, Yan B, Chng WJ.

Int J Mol Sci. 2018 Jun 10;19(6). pii: E1721. doi: 10.3390/ijms19061721. Review.

48.

Preleukemic and second-hit mutational events in an acute myeloid leukemia patient with a novel germline RUNX1 mutation.

Ng IK, Lee J, Ng C, Kosmo B, Chiu L, Seah E, Mok MMH, Tan K, Osato M, Chng WJ, Yan B, Tan LK.

Biomark Res. 2018 May 11;6:16. doi: 10.1186/s40364-018-0130-2. eCollection 2018.

49.

Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma.

Shanmugam MK, Ahn KS, Lee JH, Kannaiyan R, Mustafa N, Manu KA, Siveen KS, Sethi G, Chng WJ, Kumar AP.

Front Pharmacol. 2018 May 3;9:365. doi: 10.3389/fphar.2018.00365. eCollection 2018.

50.

Evaluation of a risk-guided strategy for empirical carbapenem use in febrile neutropenia.

Khoo AL, Zhao YJ, Teng M, Ying D, Jin J, Chee YL, Poon LM, Lim SE, Koh LP, Chng WJ, Lim BP, Hsu LY, Chai LYA.

Int J Antimicrob Agents. 2018 Sep;52(3):350-357. doi: 10.1016/j.ijantimicag.2018.04.017. Epub 2018 May 9.

PMID:
29751120

Supplemental Content

Support Center